Jun 13, 2022 / 10:20PM GMT
Nathan Allen Rich - Goldman Sachs Group, Inc., Research Division - Research Analyst
Good afternoon, everyone. Thanks a lot for joining us. Again, my name is Nathan Rich, and I cover the animal health space here at Goldman. We're pleased to welcome Elanco for our next session. We have Todd Young, CFO; and Katy Grissom from Investor Relations. Todd, very good to see you. Sorry I couldn't be there in person. COVID had its own plan. So I'm glad to have the opportunity to host virtually at least, and my colleague, Lindsay Golub, is on stage, and she'll jump in with some questions as well. We'll take questions from the audience towards the end if anyone does want to ask a question. Thanks a lot for your time this afternoon.
Questions and Answers:
Nathan Allen Rich - Goldman Sachs Group, Inc., Research Division - Research AnalystI thought we could maybe start with the company's outlook for the balance of the year, Todd, if that's okay.
Todd S. Young - Elanco Animal Health Incorporated - Executive VP of Corporate Governance and
Trustpilot
